Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.

Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA.

Genome Med. 2018 Jul 20;10(1):54. doi: 10.1186/s13073-018-0569-7.

2.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE.

Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.

3.

MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.

Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR.

Oncotarget. 2016 Apr 26;7(17):23300-11. doi: 10.18632/oncotarget.8188.

4.

Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.

Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR.

Mol Cancer Res. 2016 Mar;14(3):278-86. doi: 10.1158/1541-7786.MCR-15-0354. Epub 2015 Dec 18.

5.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR.

JAMA Oncol. 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34.

6.

Neuroimaging experience in pediatric Horner syndrome.

Kadom N, Rosman NP, Jubouri S, Trofimova A, Egloff AM, Zein WM.

Pediatr Radiol. 2015 Sep;45(10):1535-43. doi: 10.1007/s00247-015-3341-9. Epub 2015 Apr 2.

PMID:
25832988
7.

Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.

Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR.

PLoS One. 2015 Feb 6;10(2):e0117781. doi: 10.1371/journal.pone.0117781. eCollection 2015.

8.

Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma.

Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM.

Cancer Lett. 2015 Feb 28;357(2):549-56. doi: 10.1016/j.canlet.2014.12.008. Epub 2014 Dec 12.

9.

Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.

Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA.

Clin Cancer Res. 2014 Oct 1;20(19):5041-51. doi: 10.1158/1078-0432.CCR-14-0051. Epub 2014 Aug 8.

10.

Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.

Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T.

Nat Genet. 2014 Sep;46(9):939-43. doi: 10.1038/ng.3051. Epub 2014 Aug 3.

11.

Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities.

Kagawa S, Natsuizaka M, Whelan KA, Facompre N, Naganuma S, Ohashi S, Kinugasa H, Egloff AM, Basu D, Gimotty PA, Klein-Szanto AJ, Bass AJ, Wong KK, Diehl JA, Rustgi AK, Nakagawa H.

Oncogene. 2015 Apr 30;34(18):2347-59. doi: 10.1038/onc.2014.169. Epub 2014 Jun 16.

12.

Factors contributing to recurrence of oral cavity and laryngeal tumors and estimation of tumor age.

Choby GW, Albergotti WG, Byrd JK, Egloff AM, Johnson JT.

Laryngoscope. 2014 Oct;124(10):2297-304. doi: 10.1002/lary.24745. Epub 2014 Jun 10.

PMID:
24913023
13.

Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth.

Li C, Egloff AM, Sen M, Grandis JR, Johnson DE.

Mol Oncol. 2014 Oct;8(7):1220-30. doi: 10.1016/j.molonc.2014.03.018. Epub 2014 Apr 18.

14.

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.

Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R.

Ann Oncol. 2014 Jul;25(7):1410-6. doi: 10.1093/annonc/mdu167. Epub 2014 May 5.

15.

Frailty measurements and dysphagia in the outpatient setting.

Hathaway B, Vaezi A, Egloff AM, Smith L, Wasserman-Wincko T, Johnson JT.

Ann Otol Rhinol Laryngol. 2014 Sep;123(9):629-35. doi: 10.1177/0003489414528669. Epub 2014 Apr 4.

PMID:
24707011
16.

Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma.

Lei Y, Lui VW, Grandis JR, Egloff AM.

PLoS One. 2014 Jan 21;9(1):e85619. doi: 10.1371/journal.pone.0085619. eCollection 2014.

17.

Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion.

Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR, Thomas SM.

Br J Cancer. 2013 Dec 10;109(12):3049-56. doi: 10.1038/bjc.2013.624. Epub 2013 Nov 14.

18.

Revision septoplasty: a prospective disease-specific outcome study.

Gillman GS, Egloff AM, Rivera-Serrano CM.

Laryngoscope. 2014 Jun;124(6):1290-5. doi: 10.1002/lary.24356. Epub 2013 Sep 19.

PMID:
23945947
19.

SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Feb 15;19(4):798-808. doi: 10.1158/1078-0432.CCR-12-1517. Epub 2013 Jan 30.

20.
21.

Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy.

Egloff AM, Grandis JR.

Clin Cancer Res. 2012 Oct 1;18(19):5188-95. doi: 10.1158/1078-0432.CCR-11-2258. Epub 2012 Jul 6.

22.

TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression.

Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RS, Egloff AM, Chen X, Lui VW, Grandis JR, Gollin SM.

Cancer Res. 2012 Jul 1;72(13):3270-81. doi: 10.1158/0008-5472.CAN-12-0475-T. Epub 2012 May 7.

23.

Anatomic variants on computed tomography in congenital aural atresia.

Dedhia K, Yellon RF, Branstetter BF, Egloff AM.

Otolaryngol Head Neck Surg. 2012 Aug;147(2):323-8. doi: 10.1177/0194599812442866. Epub 2012 Mar 30.

PMID:
22467282
24.

Congenital cholesteatoma: predictors for residual disease and hearing outcomes.

Stapleton AL, Egloff AM, Yellon RF.

Arch Otolaryngol Head Neck Surg. 2012 Mar;138(3):280-5. doi: 10.1001/archoto.2011.1422.

PMID:
22431873
25.

Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma.

Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR.

Head Neck. 2013 Feb;35(2):270-9. doi: 10.1002/hed.22963. Epub 2012 Mar 20.

26.

Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM.

Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20.

27.

Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study.

Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM.

Respir Res. 2012 Feb 1;13:9. doi: 10.1186/1465-9921-13-9.

28.

Chemokine receptor 7 (CCR7) gene expression is regulated by NF-κB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN).

Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C, Ferris RL.

J Biol Chem. 2012 Jan 27;287(5):3581-90. doi: 10.1074/jbc.M111.294876. Epub 2011 Dec 12.

29.

TIM polymorphisms--genetics and function.

Lee J, Phong B, Egloff AM, Kane LP.

Genes Immun. 2011 Dec;12(8):595-604. doi: 10.1038/gene.2011.75. Epub 2011 Nov 3. Review.

30.

Fetal chest ultrasound and magnetic resonance imaging: recent advances and current clinical applications.

Bulas D, Egloff AM.

Radiol Clin North Am. 2011 Sep;49(5):805-23. doi: 10.1016/j.rcl.2011.06.005. Review.

PMID:
21889010
31.

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.

Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM.

Invest New Drugs. 2012 Aug;30(4):1575-84. doi: 10.1007/s10637-011-9732-3. Epub 2011 Sep 1.

32.

The mutational landscape of head and neck squamous cell carcinoma.

Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR.

Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.

33.

Response to combined molecular targeting: defining the role of P-STAT3.

Egloff AM, Grandis JR.

Clin Cancer Res. 2011 Feb 1;17(3):393-5. doi: 10.1158/1078-0432.CCR-10-2925. Epub 2011 Jan 25.

34.

Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.

Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A.

Clin Cancer Res. 2010 Apr 15;16(8):2427-34. doi: 10.1158/1078-0432.CCR-09-2658. Epub 2010 Apr 6.

35.

An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies.

Amin W, Kang HP, Egloff AM, Singh H, Trent K, Ridge-Hetrick J, Seethala RR, Grandis J, Parwani AV.

BMC Cancer. 2009 Nov 13;9:396. doi: 10.1186/1471-2407-9-396.

36.

Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.

Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP.

Clin Cancer Res. 2009 Nov 1;15(21):6529-40. doi: 10.1158/1078-0432.CCR-09-0862. Epub 2009 Oct 13.

38.

HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM.

Clin Cancer Res. 2009 Jun 1;15(11):3740-50. doi: 10.1158/1078-0432.CCR-08-3252. Epub 2009 May 26.

39.

Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.

Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR.

J Clin Oncol. 2009 Mar 10;27(8):1235-42. doi: 10.1200/JCO.2008.17.8251. Epub 2009 Feb 9.

40.

Pediatric cervical spine trauma imaging: a practical approach.

Egloff AM, Kadom N, Vezina G, Bulas D.

Pediatr Radiol. 2009 May;39(5):447-56. doi: 10.1007/s00247-008-1043-2. Epub 2008 Nov 12. Review.

PMID:
19002679
41.

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR.

Clin Cancer Res. 2008 Jul 1;14(13):4284-91. doi: 10.1158/1078-0432.CCR-07-5226.

42.

Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

Egloff AM, Grandis JR.

Semin Oncol. 2008 Jun;35(3):286-97. doi: 10.1053/j.seminoncol.2008.03.008. Review.

43.

Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression.

Chiosea SI, Barnes EL, Lai SY, Egloff AM, Sargent RL, Hunt JL, Seethala RR.

Virchows Arch. 2008 Jun;452(6):629-35. doi: 10.1007/s00428-007-0574-5. Epub 2008 Feb 1.

PMID:
18239938
44.

Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma.

Egloff AM, Grandis J.

Expert Opin Ther Targets. 2006 Oct;10(5):639-47.

PMID:
16981821
45.

Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.

Egloff AM, Weissfeld J, Land SR, Finn OJ.

Ann N Y Acad Sci. 2005 Dec;1062:29-40.

PMID:
16461786
46.

Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.

Egloff AM, Vella LA, Finn OJ.

Cancer Res. 2006 Jan 1;66(1):6-9. Review.

47.

Desmoplastic small round cell tumor of the kidney in a pediatric patient: sonographic and multiphase CT findings.

Egloff AM, Lee EY, Dillon JE, Callahan MJ.

AJR Am J Roentgenol. 2005 Nov;185(5):1347-9. No abstract available.

PMID:
16247161
48.

Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I.

Egloff AM, Desiderio S.

J Biol Chem. 2001 Jul 27;276(30):27806-15. Epub 2001 May 23.

50.

Cloning, expression, and characterization of a gene encoding the human angiotensin II type 1A receptor.

Mauzy CA, Hwang O, Egloff AM, Wu LH, Chung FZ.

Biochem Biophys Res Commun. 1992 Jul 15;186(1):277-84.

PMID:
1378723

Supplemental Content

Loading ...
Support Center